

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement does not constitute an offer, or an invitation to apply for, or an offer or invitation to purchase or subscribe for any securities either in the United States or in any other jurisdiction. Securities may not be offered, sold or delivered within the United States, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act) unless they are registered or exempt from registration under the Securities Act.



微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

BUSINESS UPDATE

Non-binding Proposal in relation to the Proposed Strategic Restructuring of the CRM Business

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”), on a voluntary basis to inform its shareholders and potential investors about the latest business development of the Group.

Background

References are made to the announcements of the Company dated 20 November 2017, 20 February 2018, 8 March 2018, 30 April 2018, 27 February 2019, 5 July 2020 and 26 July 2021 and the circular of the Company dated 3 April 2018 in relation to, among other things, the Group’s acquisition of the cardiac rhythm management (“**CRM**”) business and the subsequent contribution of new capital to, and introduction of new investors in, MicroPort Cardiac Rhythm Management Limited (“**CRM Cayman**”), a company incorporated in the Cayman Islands.

As at the date of this announcement, CRM Cayman is a non-wholly owned subsidiary of the Group which is engaged in the CRM business of the Group. As at the date of this announcement, CRM Cayman is held as to 50.13% by the Group, and as to the remaining 49.87% by other shareholders.

Non-binding proposal in relation to the proposed strategic restructuring of the CRM business

To drive deep integration and efficient collaboration of internal resources, enhance corporate competitiveness, consolidate different business segments and product portfolios and create long-term value for the Group and its relevant stakeholders, the board of directors of the Company is considering a non-binding proposal relating to the proposed strategic restructuring of the Group's CRM business, pursuant to which, subject to further negotiations with interested parties, the execution of definitive agreements and obtaining the necessary consents and approvals, the CRM business will be consolidated with the business of MicroPort CardioFlow Medtech Corporation ("**MicroPort CardioFlow**"), a company incorporated in the Cayman Islands, the shares of which are listed on the main board of The Stock Exchange of Hong Kong Limited (stock code: 2160) and a non-wholly owned subsidiary of the Company as at the date of this announcement (the "**Proposal**").

The Proposal is non-binding and does not constitute any binding offer, agreement, or commitment to make a binding offer. It does not include all terms necessary for consummating the Proposal. A binding commitment will only arise upon the execution of definitive agreements, subject to the terms and conditions therein.

Rationale for the Proposal

The Company is incorporated in the Cayman Islands and the shares of which are listed on the main board of The Stock Exchange of Hong Kong Limited. The Company, together with its subsidiaries, is a leading medical device group focusing on innovating, manufacturing and marketing high-end medical devices globally in a broad range of business segments. As at the date of this announcement, such business segments include cardiovascular devices, orthopedics devices, CRM, endovascular and peripheral vascular devices, neurovascular devices, structural heart disease business, surgical robot and other business.

The CRM business of the Group is committed to creating the world's leading CRM solutions, and principally engaged in developing, manufacturing and marketing products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, with products covering pacemakers, defibrillators, cardiac resynchronization therapy devices and supporting lead products, as well as a portfolio of monitoring products used in combination.

On the other hand, the structural heart disease business of the Group, as conducted through MicroPort CardioFlow, focuses on the R&D and commercialization of innovative transcatheter solutions for structural heart diseases and is dedicated to providing universal access to state-of-the-art total solutions to physicians and patients for the treatment of structural heart diseases.

The strategic rationale for the consolidation of the CRM business and the structural heart disease business conducted through MicroPort CardioFlow is fourfold:

1. Establishment of a heart disease product platform with diversified products and product pipelines enhancing the Group's global markets development capability

The consolidation of the two businesses can facilitate the establishment of a heart disease product platform by the Group, on which diversified products and product pipelines will be offered ranging from pacemakers, defibrillators, cardiac resynchronization therapy devices from the CRM business to TAVI products, LAA products, TMV products, TTV products and other products from the structural heart disease business. Through the establishment of such a diversified product platform, the Group will emerge as a distinctive and scarce player in the sector, offering a comprehensive portfolio encompassing both structural heart disease and CRM solutions, which will enhance the Group's global markets development capability, thus allowing the consolidated business to further strengthen its positioning within respective segments in a global context.

2. Creation of synergistic effects to both businesses through sharing of international marketing and sales channels, establishing stronger foothold and market influence in the global markets

At the moment, the products of each business are being marketed globally through direct sales and/or distributors, with ongoing cooperations between each business in certain regions, in addition to leveraging on the respective marketing and sales channels of each business. Through the consolidation of the two businesses, such global market resources can be further shared and aligned, creating synergistic effects, expanding the breadth and depth of the existing cooperation and facilitating the establishment of the Group's stronger foothold and market influence in the global markets and bringing the Group's products to more hospitals and patients.

3. Expansion of the business scale and growth potential, enhancing the revenue, profitability and cashflow of both businesses

Through the complementary synergies achieved by the consolidation of the two businesses, the business scale and growth potential of the consolidated business will be expanded, leading to enhancement in the revenue, profitability and cashflow of the consolidated business. The capital utilisation efficiency and capital raising capability can also be enhanced through unified financial management.

4. Enhancing the capital market's recognition of the underlying value and growth potential of both businesses

The promulgation of a heart disease product platform with diversified products and product pipelines to the international markets can enhance the international capital market's recognition of the underlying value and growth potential of both businesses.

General

As at the date of this announcement, the terms and conditions of the Proposal are yet to be negotiated and no legally binding agreement has been entered into by the Group. The Proposal, if materialised, may or may not constitute a notifiable transaction and/or a connected transaction of the Company under Chapters 14 and 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), respectively. The Company will issue further announcement(s) as and when appropriate, and will comply with all applicable requirements under the Listing Rules.

The Proposal is non-binding, and there is no certainty that the Proposal will proceed or be completed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company’s securities.

This announcement does not constitute an offer, or an invitation to apply for, or an offer or invitation to purchase or subscribe for any securities either in the United States or in any other jurisdiction. Securities may not be offered, sold or delivered within the United States, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act) unless they are registered or exempt from registration under the Securities Act.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the People’s Republic of China, 16 July 2025

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *for identification purpose only*